FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379162162> ?p ?o ?g. }

• W4379162162 abstract "<div>AbstractPurpose:<p>Checkpoint inhibitors have limited efficacy for children with unselected solid and brain tumors. We report the first prospective pediatric trial (NCT02992964) using nivolumab exclusively for refractory nonhematologic cancers harboring tumor mutation burden (TMB) ≥5 mutations/megabase (mut/Mb) and/or mismatch repair deficiency (MMRD).</p>Patients and Methods:<p>Twenty patients were screened, and 10 were ultimately included in the response cohort of whom nine had TMB >10 mut/Mb (three initially eligible based on MMRD) and one patient had TMB between 5 and 10 mut/Mb.</p>Results:<p>Delayed immune responses contributed to best overall response of 50%, improving on initial objective responses (20%) and leading to 2-year overall survival (OS) of 50% [95% confidence interval (CI), 27–93]. Four children, including three with refractory malignant gliomas are in complete remission at a median follow-up of 37 months (range, 32.4–60), culminating in 2-year OS of 43% (95% CI, 18.2–100). Biomarker analyses confirmed benefit in children with germline MMRD, microsatellite instability, higher activated and lower regulatory circulating T cells. Stochastic mutation accumulation driven by underlying germline MMRD impacted the tumor microenvironment, contributing to delayed responses. No benefit was observed in the single patient with an MMR-proficient tumor and TMB 7.4 mut/Mb.</p>Conclusions:<p>Nivolumab resulted in durable responses and prolonged survival for the first time in a pediatric trial of refractory hypermutated cancers including malignant gliomas. Novel biomarkers identified here need to be translated rapidly to clinical care to identify children who can benefit from checkpoint inhibitors, including upfront management of cancer.</p></div>" @default.
• W4379162162 created "2023-06-03" @default.
• W4379162162 creator A5001161042 @default.
• W4379162162 creator A5001392592 @default.
• W4379162162 creator A5001673025 @default.
• W4379162162 creator A5002431674 @default.
• W4379162162 creator A5010939758 @default.
• W4379162162 creator A5013395863 @default.
• W4379162162 creator A5017342460 @default.
• W4379162162 creator A5022274718 @default.
• W4379162162 creator A5028980058 @default.
• W4379162162 creator A5030969029 @default.
• W4379162162 creator A5031033801 @default.
• W4379162162 creator A5032075563 @default.
• W4379162162 creator A5033692158 @default.
• W4379162162 creator A5038007660 @default.
• W4379162162 creator A5044218928 @default.
• W4379162162 creator A5046351275 @default.
• W4379162162 creator A5052145351 @default.
• W4379162162 creator A5052728382 @default.
• W4379162162 creator A5054712515 @default.
• W4379162162 creator A5059269761 @default.
• W4379162162 creator A5060222946 @default.
• W4379162162 creator A5068257880 @default.
• W4379162162 creator A5068881416 @default.
• W4379162162 creator A5072207500 @default.
• W4379162162 creator A5077515719 @default.
• W4379162162 creator A5079323221 @default.
• W4379162162 creator A5086771704 @default.
• W4379162162 creator A5091889591 @default.
• W4379162162 date "2023-06-02" @default.
• W4379162162 modified "2023-09-23" @default.
• W4379162162 title "Data from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency" @default.
• W4379162162 doi "https://doi.org/10.1158/1078-0432.c.6678040" @default.
• W4379162162 hasPublicationYear "2023" @default.
• W4379162162 type Work @default.
• W4379162162 citedByCount "0" @default.
• W4379162162 crossrefType "posted-content" @default.
• W4379162162 hasAuthorship W4379162162A5001161042 @default.
• W4379162162 hasAuthorship W4379162162A5001392592 @default.
• W4379162162 hasAuthorship W4379162162A5001673025 @default.
• W4379162162 hasAuthorship W4379162162A5002431674 @default.
• W4379162162 hasAuthorship W4379162162A5010939758 @default.
• W4379162162 hasAuthorship W4379162162A5013395863 @default.
• W4379162162 hasAuthorship W4379162162A5017342460 @default.
• W4379162162 hasAuthorship W4379162162A5022274718 @default.
• W4379162162 hasAuthorship W4379162162A5028980058 @default.
• W4379162162 hasAuthorship W4379162162A5030969029 @default.
• W4379162162 hasAuthorship W4379162162A5031033801 @default.
• W4379162162 hasAuthorship W4379162162A5032075563 @default.
• W4379162162 hasAuthorship W4379162162A5033692158 @default.
• W4379162162 hasAuthorship W4379162162A5038007660 @default.
• W4379162162 hasAuthorship W4379162162A5044218928 @default.
• W4379162162 hasAuthorship W4379162162A5046351275 @default.
• W4379162162 hasAuthorship W4379162162A5052145351 @default.
• W4379162162 hasAuthorship W4379162162A5052728382 @default.
• W4379162162 hasAuthorship W4379162162A5054712515 @default.
• W4379162162 hasAuthorship W4379162162A5059269761 @default.
• W4379162162 hasAuthorship W4379162162A5060222946 @default.
• W4379162162 hasAuthorship W4379162162A5068257880 @default.
• W4379162162 hasAuthorship W4379162162A5068881416 @default.
• W4379162162 hasAuthorship W4379162162A5072207500 @default.
• W4379162162 hasAuthorship W4379162162A5077515719 @default.
• W4379162162 hasAuthorship W4379162162A5079323221 @default.
• W4379162162 hasAuthorship W4379162162A5086771704 @default.
• W4379162162 hasAuthorship W4379162162A5091889591 @default.
• W4379162162 hasConcept C104317684 @default.
• W4379162162 hasConcept C109825262 @default.
• W4379162162 hasConcept C121608353 @default.
• W4379162162 hasConcept C126322002 @default.
• W4379162162 hasConcept C13514818 @default.
• W4379162162 hasConcept C142424586 @default.
• W4379162162 hasConcept C143998085 @default.
• W4379162162 hasConcept C180754005 @default.
• W4379162162 hasConcept C2777701055 @default.
• W4379162162 hasConcept C2779767149 @default.
• W4379162162 hasConcept C2780030458 @default.
• W4379162162 hasConcept C44249647 @default.
• W4379162162 hasConcept C501734568 @default.
• W4379162162 hasConcept C502942594 @default.
• W4379162162 hasConcept C54355233 @default.
• W4379162162 hasConcept C61320498 @default.
• W4379162162 hasConcept C71924100 @default.
• W4379162162 hasConcept C72563966 @default.
• W4379162162 hasConcept C86803240 @default.
• W4379162162 hasConcept C87355193 @default.
• W4379162162 hasConceptScore W4379162162C104317684 @default.
• W4379162162 hasConceptScore W4379162162C109825262 @default.
• W4379162162 hasConceptScore W4379162162C121608353 @default.
• W4379162162 hasConceptScore W4379162162C126322002 @default.
• W4379162162 hasConceptScore W4379162162C13514818 @default.
• W4379162162 hasConceptScore W4379162162C142424586 @default.
• W4379162162 hasConceptScore W4379162162C143998085 @default.
• W4379162162 hasConceptScore W4379162162C180754005 @default.
• W4379162162 hasConceptScore W4379162162C2777701055 @default.
• W4379162162 hasConceptScore W4379162162C2779767149 @default.
• W4379162162 hasConceptScore W4379162162C2780030458 @default.
• W4379162162 hasConceptScore W4379162162C44249647 @default.
• W4379162162 hasConceptScore W4379162162C501734568 @default.
• W4379162162 hasConceptScore W4379162162C502942594 @default.

• next